All results

31 results for randomized double blind placebo controlled study assess efficacy safety and

• ATYR

  This randomized, double-blind, placebo matched to efzofitimod-controlled, study will evaluate the safety, tolerability, immunogenicity, pharmacokinetic (PK),…

  Ages

  18 Years - 75 Years

  Sexes

  All

• Adaptive COVID-19 Treatment Trial (ACTT)

  This study is an adaptive, randomized, double-blind, placebo-controlled trial to evaluate the safety and efficacy of novel therapeutic agents in hospitalized…

  Ages

  18 Years - 99 Years

  Sexes

  All

• Armata

  Phase 1b/2a, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Escalation Study of the Safety, Tolerability, and Efficacy of Intravenous AP…

  Ages

  18 Years - N/A

  Sexes

  All

• Atacicept in Subjects With IgA Nephropathy

  A Phase 3 Study with Atacicept in Subjects With IgA Nephropathy (ORIGIN 3) This is a multi-part study comprising of the original Phase 2b study (active, no…

  Ages

  18 Years - N/A

  Sexes

  All

• Avidity FSHD

  A Randomized, Double-blind, Placebo-controlled, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory…

  Ages

  18 Years - 65 Years

  Sexes

  All

• BOOST3

  BOOST3 is a randomized clinical trial to determine the comparative effectiveness of two strategies for monitoring and treating patients with traumatic brain…

  Ages

  14 Years - N/A

  Sexes

  All

• CC-90001 in Subjects With Idiopathic Pulmonary Fibrosis

  This is a Phase 2, multicenter, multinational, randomized, double-blind, placebo-controlled study evaluating the efficacy, safety, pharmacokinetics (PK),…

  Ages

  40 Years - N/A

  Sexes

  All

• CTD-TCNPC-301

  A prospective, randomized, double-blind, placebo controlled, multi-center therapeutic study for patients age 3 and older with confirmed diagnosis of Niemann…

  Ages

  3 Years - N/A

  Sexes

  All

• Efficacy and Safety of AMG 570 in Subjects With Active SLE

  The purpose of this study is to determine if Rozibafusp Alfa could be a useful therapeutic agent in the current treatment landscape where subjects with SLE…

  Ages

  18 Years - 75 Years

  Sexes

  All

• GALACTIC-1

  This is a randomized, double-blind, placebo-controlled phase 2b trial in subjects with IPF (idiopathic pulmonary fibrosis) investigating the efficacy and…

  Ages

  40 Years - N/A

  Sexes

  All